Market Overview

RBC Downgrades Intercept Pharma On Valuation, Remains Positive On Upcoming Trial Data

RBC Downgrades Intercept Pharma On Valuation, Remains Positive On Upcoming Trial Data
Related ICPT
Searching For A Treatment: NASH Investigational Drugs With Catalysts This Year
Raymond James: Gilead In NASH For The Long Haul
Intercept's Upcoming NASH Data Is A Major Pivotal Point For Success (Seeking Alpha)

Following the 90-percent year-to-date appreciation in Intercept Pharmaceutical, Inc. (NASDAQ: ICPT) shares, RBC Capital Markets considers the stock's risk-reward to be balanced. 

The Analyst

RBC Capital Markets analyst Brian Abrahams downgraded Intercept from Outperform to Sector Perform with a $115 price target.

The Thesis

RBC remains positive on the company’s Regenerate trial for patients with advanced liver fibrosis, Abrahams said in the Wednesday downgrade note. (See the analyst's track record here.) 

“ ... We continue to believe the interim REGENERATE analysis [the first half of 2019] is more likely than not to be positive,” the analyst said. 

The balanced reward-risk valuation is driven by the considerable rise in share price, Abrahams said. While expectations for trials such as REGENERATE and NASH have not altered, the analyst said they were overly discounted before the run-up. 

Peer NASH company valuations illustrate similar expectations, Abrahams said. 

“Interestingly, we note that the gap in valuation between ICPT and Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) has closed ... further suggesting we may have reached a more balanced relative level."

Price Action

Intercept shares were trading down 7.3 percent to $103.50 at the time of publication Wednesday.

Related Links:

Analysts Split On How To Read Intercept Switching Clinical Trial Endpoints

Will Intercept Stock Potential Be Blindsided By FDA Letter?

Latest Ratings for ICPT

Jan 2019Laidlaw & Co.UpgradesNeutralBuy
Dec 2018B. Riley FBRInitiates Coverage OnBuy
Nov 2018OppenheimerUpgradesPerformOutperform

View More Analyst Ratings for ICPT
View the Latest Analyst Ratings

Posted-In: Brian Abrahams RBC Capital MarketsAnalyst Color Biotech Downgrades Price Target Analyst Ratings General Best of Benzinga


Related Articles (ICPT + MDGL)

View Comments and Join the Discussion!

Latest Ratings

CNPRBC CapitalUpgrades34.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Cowen: Columbia Sportswear's Share Price Doesn't Reflect Portfolio Strength

Nvidia Gets Double Upgrade Ahead Of Earnings